Franken, Linda G.
Francke, Marith I.
Andrews, Louise M.
van Schaik, Ron H. N.
Li, Yi
de Wit, Lucia E. A.
Baan, Carla C.
Hesselink, Dennis A.
de Winter, Brenda C. M
Article History
Accepted: 16 March 2022
First Online: 20 April 2022
Declarations
:
: D.A. Hesselink has received grant support (paid to his institution) from Astellas Pharma, Chiesi Farmaceutici SpA, and Bristol Myers-Squibb, as well as lecture and consulting fees from Astellas Pharma, Chiesi Farmaceutici SpA, Novartis Pharma, and Vifor Pharma. All other authors declared no competing interests for this work.
: This study was a post-hoc analysis of a randomized controlled trial [CitationRef removed] (Dutch National Trial Registry number NTR2226). For the present study, the Ethics Review Board of the Erasmus MC provided a waiver for the Medical Research Involving Human Subjects Act for this study (Medical Ethical Review Board number 2017–1029). All study procedures were in accordance with the principles of the Declaration of Helsinki.
: Written informed consent was obtained from all patients before inclusion in the previous trial by Shuker et al. [CitationRef removed].